Cargando…
Immunotherapy in non-small cell lung cancer: Past, present, and future directions
Many decades in the making, immunotherapy has demonstrated its ability to produce durable responses in several cancer types. In the last decade, immunotherapy has shown itself to be a viable therapeutic approach for non-small cell lung cancer (NSCLC). Several clinical trials have established the eff...
Autores principales: | Punekar, Salman R., Shum, Elaine, Grello, Cassandra Mia, Lau, Sally C., Velcheti, Vamsidhar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382405/ https://www.ncbi.nlm.nih.gov/pubmed/35992832 http://dx.doi.org/10.3389/fonc.2022.877594 |
Ejemplares similares
-
The current state of the art and future trends in RAS-targeted cancer therapies
por: Punekar, Salman R., et al.
Publicado: (2022) -
Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1
por: Velcheti, Vamsidhar, et al.
Publicado: (2022) -
Past, Current, and Future of Immunotherapies for Prostate Cancer
por: Boettcher, Adeline N., et al.
Publicado: (2019) -
Immunotherapy of Brain Cancers: The Past, the Present, and Future Directions
por: Ge, Lisheng, et al.
Publicado: (2010) -
Immunotherapy in non‐small cell lung cancer: The past, the present, and the future
por: Lu, Meng, et al.
Publicado: (2019)